Welcome. Who is here? What is this?

Here's news and info about three primary blood cancers, Lymphoma, Myeloma and Leukemia with a decided patient's perspective.  I hope this helps whether you're newly diagnosed or veteran survivor.  

       Is this You?              This is me.            We're Not Alone!    

 Is this You cancer patient    Click This is me    We are not alone, cancer warriors
Check my:Link to my blog

 

Twitter Feed

Click my Social Media, good stuff

YouTube -- https://www.youtube.com/user/JackWhelanAdvocate Twitter -- https://twitter.com/JackWhelan Google+ -- http://www.google.com/+JackWhelanAdvocate Facebook -- https://www.facebook.com/jack.whelan.98031

AACR Legislative: Write your Congressmen!

LinkedIn

Professional Research Advocacy

 

American Association for Cancer Research

 

 American Society of Clinical Oncology 

 

Alliance for Clinical Research Excellence and Safety

  

National Organization for Rare Diseases 

Rare Disease Legislative Advocates  

Research Advocacy Network 

Alliance for Clinical Trials Oncology, Jack Whelan member

Patient Advocates In

Society for Participatory Medicine

Health Advocate Code of Conduct and Professional Standards

WEGO Health Speakers Bureau 

Connect With Me At ExpertFile

 

Music and audio player

As seen or quoted on these TV stations

ABC Good Morning America CBS Sunday Morning 2 News 3 News 8 10 News 12 News WIDK 10 28 News KCOY KCAU 9 KILL TV3 KLTV 7 KMPH 26 KOTA 28 News America my FOX LIVE HD 5 blip 28 News FOX-25 FOX-5 NEWS-25HD KYTX-19 NBC4i NBC29 ABC 33-40 WAND 17HD WBAY 2 WBOC 16 WECT 6 WHBQ 13 WITN WLBT 3 WMCT 5 WRCB 3 WSET 13 WTOC 11 WTVM 9 WVUE 8

What role will Companion Diagnostics (CDx) play in the future

What role will companion diagnostics play in the future of Oncology?

Recently Bryson Velletri Business Development Intern at Publicis Touchpoint Solutions wrote:

Companion diagnostics give Oncologists the ability to segment cancer patients based on specific growth factor expressions (MET test, HER test, EGFR test etc.) . This segmentation allows for more personalized, targeted treatment due in part to the presence of specific growth factors. Diagnostics also allow Oncologists to determine if a patient will respond to a certain treatment regimen, saving the MCO $, and giving the patient a better outcome. 

Do you think companion diagnostics are a trend or do you think that as we attack cancers from multiple pathways, they will take a larger role?

  • Great question, Bryson. I got to speak at and meet up with many fabulous Companion Diagnostics (CDx) professionals at the World CDx 2013 Conference in Boston last week. I don't come from "the industry", so I was shocked at how little compensation (fee for service or price schedule) is paid for these much-needed CDx. The industry needs to do a better job establishing "real value" of these diagnostics that can dramatically lower the cost of healthcare services and improve the safety and efficacy of so many drugs. The industry has to show payers and lawmakers the real value of CDx; they should not be based on historical price schedules. This is particularly important in Cancer Therapy where we continue to use the empirical approach (keep trying until we find what works) rather than genomics-based (learn about the target, the pathways, the molecules that respond....) taking a more precise targeted approach to care. New targeted agents (many still in Clinical Trials) can be safer and more effective than conventional chemotherapy if we use CDx. 

    Imagine receiving only $125 (typical) for a test that would determine the efficacy and safety of a drug that would be given by way of a 4 hour infusion. Imagine the savings if we knew whether the drug would be effective. Unfortunately, new provisions of the Affordable Care Act don't address this serious problem and in fact further "enable" such low fees. A new generation of Molecular Diagnostics (MDx) to analyze biomarkers in the genome and proteome—in our individualized genetic code and how their cells express their genes as proteins brings us closer to the promise of Personalized Medicine. We shouldn't take a broad brush approach to pricing diagnostics especially when considering the benefits of personalized/precision medicine. We should be willing to pay more for a weapon that does a better job hitting the target, in the right patient, at the right dose and the right time.

Comments

From Johnny | On January 03, 2014 @10:55 am
hi,My blog URL is www.cervicalrelief.com while using webmaster tool,I had used "Google with fetch". By mtaksie i had selected default URL with all linked pages option, i think my all new and old pages had gone for fetch, But after 1 day my impression came down 3Lakh to 90k and click 15k to 8k, Any help to get back all statics. Will it be ok in future? Kindly help me.
From Joseph Riordan | On November 28, 2013 @06:58 pm
Wonder if regulators have any understanding for the need for profitability so these CDx businesses can survive. They need to redefine diagnostics, this ain't your uncle's blood test. Betcha they don't know bio markers. Joe

Leave a comment

  •